Clinical Trial Update: An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating JNJ-64041757 plus nivolumab versus nivolumab alone in advanced lung adenocarcinoma; the trial was terminated and results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma

Drugs mentioned

• JNJ-64041757
• nivolumab (nivolumab)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Adenocarcinoma of Lung | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-12-11